Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

10.0K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.0K
Structure and Function of Platelets01:18

Structure and Function of Platelets

4.1K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
4.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A low dose is better than no dose: Is it time to consider lowering the US minimum plateletpheresis yield?

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2026
Same author

Management challenge of a rare concomitant platelet glycoprotein IV/CD36 and IIb/IIIa deficiencies: Case illustration.

Transfusion·2025
Same author

Erythrocytapheresis as a strategy to manage anemia and iron overload in nondeletional hemoglobin H disease.

EJHaem·2025
Same author

Management of human leukocyte antigen-mediated platelet transfusion refractoriness: Brief synopsis and recent literature review.

Transfusion·2024
Same author

How do we ensure a safe ABO recheck process?

Transfusion·2023
Same author

New Developments in the Understanding and Treatment of Autoimmune Hemolytic Anemia: Traditional and Novel Tests.

Hematology/oncology clinics of North America·2022

Related Experiment Video

Updated: Feb 28, 2026

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination
10:32

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination

Published on: August 24, 2015

14.1K

Bacterial Risk Mitigation Strategies for Platelets: Where Are We Now?

Tristan F P McKnight1, Patricia Kopko1

  • 1Department of Pathology, Division of Laboratory and Genomic Medicine, University of California San Diego, San Diego, CA, USA.

Clinics in Laboratory Medicine
|February 25, 2026
PubMed
Summary

Bacterial contamination of platelets persists despite safety measures like pathogen reduction. Continued vigilance and reporting are crucial for safe platelet transfusions.

Keywords:
BacteriaContaminationLVDSMitigationPathogen-reductionPlateletsRiskTransfusion

More Related Videos

Routine Screening Method for Microparticles in Platelet Transfusions
09:49

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

16.6K
Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

29.6K

Related Experiment Videos

Last Updated: Feb 28, 2026

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination
10:32

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination

Published on: August 24, 2015

14.1K
Routine Screening Method for Microparticles in Platelet Transfusions
09:49

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

16.6K
Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

29.6K

Area of Science:

  • Transfusion Medicine
  • Hematology
  • Microbiology

Background:

  • Bacterial contamination of platelet products is a significant risk in transfusion medicine.
  • Current Food and Drug Administration-recommended strategies have not completely eliminated this risk.

Purpose of the Study:

  • To highlight the persistent challenge of bacterial contamination in platelet transfusions.
  • To emphasize the limitations of existing mitigation strategies, including pathogen reduction technology.

Main Methods:

  • Review of current bacterial contamination mitigation strategies for platelet products.
  • Analysis of recent incidents and limitations of pathogen reduction technologies.

Main Results:

  • Despite mitigation efforts, bacterial contamination of platelets remains a threat.
  • Pathogen reduction technology, while beneficial, does not guarantee sterility.

Conclusions:

  • Existing safety measures are insufficient to eliminate the risk of bacterial contamination in platelets.
  • Ongoing hemovigilance and diligent reporting are essential for ensuring the safety of platelet transfusions.